ubet63 apk download

ubet63 apk download AP Sports SummaryBrief at 6:40 p.m. EST

JACKSONVILLE, Fla. (AP) — Keaston Willis scored 15 points off of the bench to help lead Tulsa over Detroit Mercy 63-44 on Tuesday. Willis finished 3 of 9 from 3-point range and 6 for 7 from the line for the Golden Hurricane (4-3). Isaiah Barnes scored 12 points while shooting 4 for 9, including 4 for 6 from beyond the arc and added seven rebounds. Dwon Odom had 11 points and went 5 of 8 from the field. Jared Lary led the way for the Titans (3-4) with 12 points and two steals. Tulsa led 36-27 at halftime, with Willis racking up nine points. Tulsa extended its lead to 54-35 during the second half, fueled by a 9-2 scoring run. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Lewandowski hits Champions League century as Barca beat Brest

I’m a 50-year-old marketing executive; I purchased a ₹10-lakh health insurance policy 10 years ago. Recently, I’ve been diagnosed with hypertension and require daily medication. Will my policy cover the costs of these medications, or are they considered part of a pre-existing condition since hypertension often develops gradually? If it’s viewed as a pre-existing condition, how long will I have to wait before related expenses are covered? Also, will future complications arising from hypertension, such as cardiac issues, be covered under my policy? Sunita Navigating health challenges is a reality many individuals face, and having comprehensive health insurance is essential for safeguarding your well-being. It is recommended to maintain health insurance coverage of two-three times your income, so based on that you might want to reassess the ₹10-lakh health insurance policy, purchased 10 years ago. This coverage becomes especially critical as health needs typically evolve with age. Regarding your recent diagnosis of hypertension, you can be confident that all hospitalisation expenses related to this condition will be covered under your policy. Since hypertension often develops gradually, it’s important to clarify that because your diagnosis occurred after the policy was issued, it will not be classified as a pre-existing condition in your case. This means you do not have to wait for coverage for future hospitalisations related to hypertension. Moreover, your policy includes provisions for pre-hospitalisation and post-hospitalisation expenses. This means that any necessary medications and consultations related to your hypertension — both before and after hospitalisation — are covered. Specifically, expenses incurred up to a defined number of days prior to your admission, as well as costs for a certain duration after discharge, will be reimbursed according to your policy terms. This can include diagnostic tests, consultations with your healthcare provider and prescribed medications, all within the policy limits. It would be advisable to opt for an Outpatient Department (OPD) cover so that your coverage will be even more comprehensive. OPD benefits allow you to claim expenses for consultations, diagnostic tests and medications without requiring hospitalisation. This feature is particularly advantageous for managing chronic conditions like hypertension, which often necessitate ongoing medical care and regular medication. If you have chosen an OPD cover, routine doctor visits and prescription medications will also be covered, subject to the terms of that rider. Any complications arising from hypertension, such as cardiac conditions, will also be covered under your policy. This comprehensive approach ensures you are protected from the financial burden of medical expenses associated with serious health complications related to hypertension. According to WHO, one in five adults have hypertension. Effectively managing hypertension, however, is crucial for maintaining overall health and reducing the risk of serious complications, such as heart disease, stroke, and kidney problems, enhancing your overall well-being. A few insurers offer wellness programmes specifically designed to help manage chronic conditions like hypertension. These programmes can provide valuable resources and strategies to empower you to take control of your health. Choosing an insurer that has a long track record of settling claims and also invests in providing you with wellness initiatives can be an important step in proactively managing your condition while ensuring you remain covered for any future medical events. The writer is MD and CEO, Star Health and Allied Insurance CommentsPresident-elect Donald Trump asked the Supreme Court on Friday to pause the potential TikTok ban from going into effect until his administration can pursue a “political resolution” to the issue. The request came as TikTok and the Biden administration filed opposing briefs to the court, in which the company argued the court should strike down a law that could ban the platform by Jan. 19 while the government emphasized its position that the statute is needed to eliminate a national security risk. “President Trump takes no position on the underlying merits of this dispute. Instead, he respectfully requests that the Court consider staying the Act’s deadline for divestment of January 19, 2025, while it considers the merits of this case,” said Trump’s amicus brief, which supported neither party in the case and was written by D. John Sauer, Trump’s choice for solicitor general. The argument submitted to the court is the latest example of Trump inserting himself in national issues before he takes office. The Republican president-elect has already begun negotiating with other countries over his plans to impose tariffs, and he intervened earlier this month in a plan to fund the federal government, calling for a bipartisan plan to be rejected and sending Republicans back to the negotiating table. He has been holding meetings with foreign leaders and business officials at his Mar-a-Lago club in Florida while he assembles his administration, including a meeting last week with TikTok CEO Shou Chew. Trump has reversed his position on the popular app, having tried to ban it during his first term in office over national security concerns. He joined the TikTok during his 2024 presidential campaign and his team used it to connect with younger voters, especially male voters, by pushing content that was often macho and aimed at going viral. He said earlier this year that he still believed there were national security risks with TikTok, but that he opposed banning it. The filings Friday come ahead of oral arguments scheduled for Jan. 10 on whether the law, which requires TikTok to divest from its China-based parent company or face a ban, unlawfully restricts speech in violation of the First Amendment. The law was was signed by President Joe Biden in April after it passed Congress with broad bipartisan support. TikTok and ByteDance filed a legal challenge afterwards. Earlier this month, a panel of three federal judges on the U.S. Court of Appeals for the District of Columbia Circuit unanimously upheld the statute , leading TikTok to appeal the case to the Supreme Court. The brief from Trump said he opposes banning TikTok at this junction and “seeks the ability to resolve the issues at hand through political means once he takes office.” In their brief to the Supreme Court on Friday, attorneys for TikTok and its parent company ByteDance argued the federal appeals court erred in its ruling and based its decision on “alleged ‘risks’ that China could exercise control” over TikTok’s U.S. platform by pressuring its foreign affiliates. The Biden administration has argued in court that TikTok poses a national security risk due to its connections to China. Officials say Chinese authorities can compel ByteDance to hand over information on TikTok’s U.S. patrons or use the platform to spread or suppress information. But the government “concedes that it has no evidence China has ever attempted to do so,” TikTok’s legal filing said, adding that the U.S. fears are predicated on future risks. In its filing Friday, the Biden administration said because TikTok “is integrated with ByteDance and relies on its propriety engine developed and maintained in China,” its corporate structure carries with it risk.

PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications. Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq. Vincerx is also implementing additional streamlining and cost-control measures, including a workforce reduction, as it pursues due diligence and transaction-related work. As part of this workforce reduction, Dr. Ahmed Hamdy, Chairman and Chief Executive Officer (CEO), has stepped down as CEO but will remain as Chairman. Dr. Raquel Izumi has stepped down as President and Chief Operations Officer and taken over as Acting CEO in a consulting capacity. Alexander Seelenberger has stepped down as Chief Financial Officer, and Kevin Hass, the Company’s Vice President and Controller, has taken over as Acting Chief Financial Officer. Mr. Seelenberger has agreed to provide ongoing assistance in a consulting capacity to assist the Company as it pursues its strategic efforts. “This strategic transaction highlights Vincerx’s commitment to develop ADCs with improved safety profiles that allow patients to thrive on—rather than endure—their cancer therapies,” said Raquel Izumi, Ph.D., Acting Chief Executive Officer. “Oqory’s anti-TROP2 ADC has shown favorable efficacy and safety in the clinic. Among approximately 150 treated patients, results include an 83% overall response rate and 100% disease control rate in first-line triple-negative breast cancer (TNBC; n=30). Unlike other TROP2 ADCs in Phase 3, no cases of interstitial lung disease or Grade 3 and above stomatitis have been reported. Oqory’s Phase 3 studies of OQY-3258 are ongoing to confirm these promising findings.” About OQY-3258 (also known as ESG401) OQY-3258 is Oqory’s anti-TROP2 ADC with an optimized enzyme-dependent linker technology and an SN-38 payload with established efficacy and manageable side effect profile. OQY-3258 has completed Phase 1/2 development in over 150 patients with solid tumors, including metastatic HR+/HER2- and triple-negative breast cancer. OQY-3258 has shown efficacy in these patients, including reduction of brain metastasis and responses in heavily pretreated patients. To date, OQY-3258 has exhibited a differentiated safety profile vs. Trodelvy and other TROP2 ADCs in Phase 3 development. Notably, no interstitial lung disease or ocular surface events have been observed. Gastrointestinal effects have been mild and mainly Grade 1/2. Neutropenia and leukopenia have been the major AEs, which were manageable and did not result in discontinuation of study drug. OQY-3258 is being evaluated in a Phase 3 study as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer ( NCT06732323 ) and in a Phase 3 study in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer ( NCT06383767 ). About Oqory, Inc. Oqory, Inc. is an innovator in the field of ADCs with expertise in advancing targeted cancer therapies. The Company’s pipeline includes multiple ADC programs, with two currently in clinical development and several next-generation ADCs in preclinical stages. These programs are designed to address critical unmet needs in indications such as breast cancer, non-small cell lung cancer, small cell lung cancer, multiple myeloma, and other metastatic solid tumors. Powered by a proprietary ADC platform, Oqory is delivering therapies that have demonstrated promising efficacy and safety paving the way for improved patient outcomes. About Vincerx Pharma, Inc. Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx’s pipeline consists of a next-generation ADC, VIP943, currently in Phase 1; a small molecule drug conjugate, VIP236, which has completed its Phase 1 study; a CDK9 inhibitor, enitociclib, which has completed a Phase 1 monotherapy study; a preclinical ADC, VIP924; and VersAptxTM, a versatile, next-generation bioconjugation platform. Vincerx is based in Palo Alto, California, and has a research subsidiary in Monheim, Germany. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “suggest,” “seek,” “intend,” “plan,” “goal,” “potential,” “on-target,” “on track,” “project,” “estimate,” “anticipate,” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, the entry into a definitive merger agreement; the anticipated terms and closing of the merger, the $20 million equity investment, and the amount and timing of the interim financing; the expected ownership structure and value to Vincerx stockholders upon closing of the merger; the anticipated benefits of a merger transaction; and the clinical results of Oqory’s product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations, and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside Vincerx’s control. Actual results, conditions, and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions, and events to differ materially from those indicated in the forward-looking statements include, but are not limited to, Vincerx’s capital requirements, availability and sufficiency of capital, and cash runway; the ability of the parties to enter into a definitive merger agreement and the final terms thereof; the parties’ ability to satisfy the conditions precedent to the merger, including stockholder approval; the closing of the merger; the risk that any definitive agreement is terminated after it is entered into but before consummation of any proposed merger;; Vincerx’s reliance on receipt of interim funding; market acceptance of the combined company; risks associated with clinical development of the Vincerx and Oqory product candidates; general economic, financial, legal, political, and business conditions; and the risks and uncertainties set forth in Vincerx’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and subsequent reports filed with the Securities and Exchange Commission by Vincerx. Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements. Vincerx and the Vincerx logo are trademarks of Vincerx. This press release also contains trademarks and trade names that are the property of their respective owners. Contacts: Gabriela Jairala Vincerx Pharma, Inc. gabriela.jairala@vincerx.com Totyana Simien Inizio Evoke Comms totyana.simien@inizioevoke.com

Bitcoin’s ‘Kimchi Premium’ jumps amid South Korean political turmoilBOULDER — Exhale, Colorado fans. Friday's regular-season finale won’t be the final time Shedeur Sanders and Travis Hunter put on the Buffaloes uniform. “We’ve got a bowl game. I’m pretty sure we secured that weeks ago for Peggy (Coppom),” Deion Sanders said Tuesday. “It’s not the last time you’re gonna see them in a Buff uniform.” It was a fair question. With both Shedeur and Hunter projected to be picked near the top of the 2025 NFL draft, they would be far from the first (or last) stars to sit out a bowl game. Hunter said last week he wouldn’t, nor would he believe anyone else would skip out on a College Football Playoff game. Colorado quarterback Shedeur Sanders prepares to call a play during the first half of an NCAA college football game against Kansas, Saturday, Nov. 23, 2024, in Kansas City, Mo. (AP Photo/Charlie Riedel) The Buffs are still in play for a Big 12 championship, but they would need help this weekend. Coach Prime believes the team owes it to the fans to wear the Colorado uniform for the duration of the season. No. 23 Colorado hosts Oklahoma State at 10 a.m. Friday. “These two and all the rest of the seniors have done a wonderful job of getting us to where we are, installing much expectation in our fan base and expectation in ourselves,” Deion said. “We’re gonna fight and try to go out there and kick some butt and end this thing on the right note. We’re gonna go to a bowl game and end this thing on the right note because our fans deserve the absolute best and I feel like whatever bowl game we’re chosen to go to or whatever we choose, we’re gonna pack it, we’re gonna do what we normally do wherever we go on the road and it’s gonna be a tremendous game. “You’re gonna see everything you’ve seen throughout the season, regarding our athletes.” It would also be the last time Coach Prime would share the field with his sons, Shedeur and Shilo, and Hunter, whom he considers to be like a son. The trio will be off to the NFL next year. A final game with his sons, whenever it comes, isn’t on Coach Prime’s mind right now. “I’m not focused on my last hoorah with my kids, I’m focused on winning this last game with my team,” he said. Deion Sanders is ready to give back one of his trophies. Travis Hunter was named a finalist for four major college football awards on Tuesday: the Maxwell (best player), Walter Camp (best player), Bednarik (best defensive player) and Biletnikoff (best wide receiver). Hunter already had been named a finalist for the Paul Hornung award, which he won last season as college football's most versatile player. But it was the one he wasn’t a finalist for that bothered Coach Prime. Kansas wide receiver Luke Grimm (11) and Colorado corner back Travis Hunter (12) talk between plays during the first half of an NCAA college football game, Saturday, Nov. 23, 2024, in Kansas City, Mo. (AP Photo/Charlie Riedel) “How is Travis Hunter snubbed by the Jim Thorpe Award?” Sanders asked a room of reporters in attendance for his weekly press conference. The award is given annually to the country’s top defensive back and Sanders was bewildered that his star cornerback wasn’t among the three finalists. It’s an award Sanders won in 1988 during his final season at Florida State. “You can have my award. You can have it back,” Coach Prime said. “Matter of fact, I’m gonna give him (my trophy). I ain’t using it. It’s just sitting up there collecting dust. Travis can have my Thorpe Award because if this ain’t the most idiotic thing in college football that he’s not a finalist for the Jim Thorpe Award and he is, I would say arguably, but I don’t think it’s really an argument about this young man being the best defensive back in college football.” It is fair to wonder how Hunter is a finalist for the award given to the nation’s best overall defender, but not a finalist for the award for his specific defensive position. “He rarely gets thrown at, he’s won a game (by) tackling for us and he’s always on point,” Sanders said. “If you bring up statistics, I don’t know how in the world Travis Hunter is not a finalist for the Jim Thorpe Award. They just pretty much messed up all the integrity of the award. He can have mine. I don’t even want mine now.” Shedeur Sanders was also named a finalist for a major award, as he is one of three players up for the Davey O’Brien Award, given annually to the nation’s top quarterback.

No. 5 Iowa State beats Colorado 99-71 to claim fifth place at the Maui InvitationalHUMBOLDT, Tenn. (AP) — A Tennessee man was convicted Thursday of killing two men and wounding a third in a shooting at a high school basketball game three years ago. Jadon Hardiman, 21, was found guilty in Gibson County of charges including second-degree murder, attempted murder, aggravated assault and weapons offenses, district attorney Frederick Agee said in a statement. He faces up to 76 years in prison at sentencing in April. Hardiman, of Jackson, attended a basketball game between Humboldt and North Side high schools on Nov. 30, 2021. Then 18, Hardiman entered the Humboldt gymnasium's crowded concession area and pulled a semi-automatic .40 caliber handgun, prosecutors said. He fired three shots at Justin Pankey, a 21-year-old former Humboldt basketball player. Pankey was hit one time and died within seconds, Agee said. A second bullet hit Xavier Clifton, a former North Side student and basketball player, who was standing in the concession line. Clifton was shot in the neck and paralyzed. He died in March 2022. A third shot struck another man in the back of the head. He survived. “Many people were placed in fear of imminent bodily injury by Hardiman’s shooting, as shown by video footage of their fleeing into the gym, into bathrooms, and other areas of the school,” Agee said. Hardiman ran away and drove to Jackson, disposing of the murder weapon along the way, the district attorney said. The U.S. Marshals Service contacted his family, and he was arrested the next day. Agee said the shooting "frightened every adult, student, and child present, who were only there to support their team and enjoy a good game.” Hardiman's lawyer did not immediately return a call seeking comment.Ophthalmic Packaging Market Worldwide Industry Analysis, Future Demand and Forecast till 2031